BioPharmSignal logoBioPharmSignal

Biotech News

Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

Syndax Pharmaceuticals (SNDX)Syndax PharmaceuticalsEarnings

NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, April 30,

Open original release

Related news

SNDXSyndax Pharmaceuticals2026-05-12 14:31 EST

Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

SNDXSyndax Pharmaceuticals2026-05-21 21:01 EST

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

GERNGeron2026-07-22 11:00 EST

Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026

TEVATeva Pharmaceutical Industries2026-06-18 20:30 EST

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

IMTXImmatics2026-05-12 11:00 EST

Immatics Announces First Quarter 2026 Financial Results and Business Update

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

LYELLyell Immunopharma2026-05-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

View all latest news

Syndax Pharmaceuticals

Syndax Pharmaceuticals is an oncology company with programs in hematology and solid tumors, including targeted therapies and commercial assets. Its story blends launch execution with pipeline expansion.

Recent company news

SNDXSyndax Pharmaceuticals2026-06-04 11:00 EST

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

SNDXSyndax Pharmaceuticals2026-06-02 20:01 EST

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

SNDXSyndax Pharmaceuticals2026-06-01 11:00 EST

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

SNDXSyndax Pharmaceuticals2026-05-21 21:01 EST

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

SNDXSyndax Pharmaceuticals2026-05-20 11:00 EST

Syndax Announces Participation in Upcoming Investor Conferences

Stock data

Close
20.52 USD
Market cap
1.63B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States